Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2020 in Advanced Squamous Non-small Cell Lung Cancer
NCT07638891Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HDM2020 in squamous cell carcinoma of the lung (SCCL), sponsored by Huadong Medicine. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 2 years, Objective response rate up to 2 years and 5 more. Started Apr 2026; status: recruiting.
02
Drugs
HDM2020
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07638891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638891.